WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · SCR 29

Summary of SCR 29: Requesting the Auditor to Assess the Social and Financial Effects of Mandatory Health Insurance Coverage for Biomarker Testing

Bill Overview

Bill Number: SCR 29
Title: Requesting the Auditor to Assess the Social and Financial Effects of Mandatory Health Insurance Coverage for Biomarker Testing
Status: Referred to Health and Human Services (HHS) and Ways and Means (WAM)
Introduced: March 04, 2025
Classification: Concurrent Resolution
Subject: Auditor, Biomarker Testing, Mandatory Health Insurance Coverage, Social and Financial Impact Assessment Report

Purpose and Intent

SCR 29 aims to direct the state auditor to conduct a comprehensive assessment of the social and financial implications of implementing mandatory health insurance coverage for biomarker testing. Biomarker testing is increasingly recognized for its potential to enhance personalized medicine, but the financial and social impacts of mandating such coverage require thorough evaluation.

Key Provisions

  • Assessment Requirement: The resolution requests that the auditor evaluate both the social and financial effects of requiring health insurance plans to cover biomarker testing.
  • Scope of Evaluation: The assessment will likely include:
    • Cost Analysis: Estimating the financial burden on insurance providers and the potential impact on insurance premiums for consumers.
    • Access and Equity: Evaluating how mandatory coverage might affect patient access to biomarker testing and whether it promotes equitable healthcare outcomes.
    • Health Outcomes: Investigating potential improvements in health outcomes resulting from increased access to biomarker testing.

Affected Parties

  • Insurance Providers: Health insurance companies may face changes in policy requirements and financial implications due to mandatory coverage.
  • Healthcare Consumers: Patients who may benefit from biomarker testing could see changes in their access to these services and associated costs.
  • Healthcare Providers: Medical professionals may need to adapt to new coverage requirements and potentially increased demand for biomarker testing services.

Procedural Aspects

  • Legislative Actions:
    • March 4, 2025: Offered in the legislature.
    • March 6, 2025: Referred to the Health and Human Services (HHS) and Ways and Means (WAM) committees for further consideration.

Related Legislation

  • HCR 35: This is a companion bill that may address similar issues or provide additional context to the discussions surrounding biomarker testing and health insurance coverage.

Conclusion

SCR 29 represents a significant step towards understanding the implications of mandatory health insurance coverage for biomarker testing. By requesting a thorough assessment from the state auditor, the resolution seeks to ensure that any future policy decisions are informed by comprehensive data on both social and financial impacts.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.